The CMS Innovation Center has debuted a new model to encourage the use of technology to treat chronic diseases, which could be a boon for health tech companies that have struggled with reimbursement.

Before me is an expansive, arid landscape—a realm of valleys, chasms, and crevasses, of steep cliffs and dusty soil, framed by distant mountains. It might as well be on the moon itself, save for the ...

My name is Todd Tushla, I'm the Vice President of Investor Relations at Neurocrine Biosciences. And on behalf of our entire company, welcome to our 2025 R&D Day, whether you're here in person, on the ...